Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
-
Published:2017-03-28
Issue:1
Volume:8
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Huang Kuan-lin, Li Shunqiang, Mertins Philipp, Cao Song, Gunawardena Harsha P., Ruggles Kelly V.ORCID, Mani D. R., Clauser Karl R., Tanioka Maki, Usary Jerry, Kavuri Shyam M., Xie Ling, Yoon Christopher, Qiao Jana W, Wrobel John, Wyczalkowski Matthew A.ORCID, Erdmann-Gilmore Petra, Snider Jacqueline E., Hoog Jeremy, Singh Purba, Niu Beifang, Guo Zhanfang, Sun Sam Qiancheng, Sanati Souzan, Kawaler Emily, Wang Xuya, Scott Adam, Ye Kai, McLellan Michael D., Wendl Michael C., Malovannaya Anna, Held Jason M., Gillette Michael A., Fenyö David, Kinsinger Christopher R., Mesri Mehdi, Rodriguez Henry, Davies Sherri R., Perou Charles M., Ma Cynthia, Reid Townsend R., Chen Xian, Carr Steven A., Ellis Matthew J., Ding LiORCID
Abstract
AbstractRecent advances in mass spectrometry (MS) have enabled extensive analysis of cancer proteomes. Here, we employed quantitative proteomics to profile protein expression across 24 breast cancer patient-derived xenograft (PDX) models. Integrated proteogenomic analysis shows positive correlation between expression measurements from transcriptomic and proteomic analyses; further, gene expression-based intrinsic subtypes are largely re-capitulated using non-stromal protein markers. Proteogenomic analysis also validates a number of predicted genomic targets in multiple receptor tyrosine kinases. However, several protein/phosphoprotein events such as overexpression of AKT proteins and ARAF, BRAF, HSP90AB1 phosphosites are not readily explainable by genomic analysis, suggesting that druggable translational and/or post-translational regulatory events may be uniquely diagnosed by MS. Drug treatment experiments targeting HER2 and components of the PI3K pathway supported proteogenomic response predictions in seven xenograft models. Our study demonstrates that MS-based proteomics can identify therapeutic targets and highlights the potential of PDX drug response evaluation to annotate MS-based pathway activities.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference51 articles.
1. Green, E. D. & Guyer, M. S. National Human Genome Research, I. Charting a course for genomic medicine from base pairs to bedside. Nature 470, 204–213 (2011). 2. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012). 3. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382–396 (2015). 4. Simon, R. & Roychowdhury, S. Implementing personalized cancer genomics in clinical trials. Nat. Rev. Drug Discov. 12, 358–369 (2013). 5. Chin, L., Andersen, J. N. & Futreal, P. A. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17, 297–303 (2011).
Cited by
118 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|